| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,320,000 |
| Market
Cap: |
4.33(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.34 - $4.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in development for the potential treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase (SCD). Inhibition of SCD in multiple cellular systems, including patient-derived neurons, as well as in a mouse model of Parkinson's disease, has been demonstrated to reverse the toxicity of misfolded alpha-synuclein, a protein strongly associated with Parkinson's disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,250 |
50,250 |
57,251 |
| Total Buy Value |
$0 |
$37,160 |
$130,875 |
$174,456 |
| Total People Bought |
0 |
3 |
6 |
6 |
| Total Buy Transactions |
0 |
6 |
16 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
47,617 |
| Total Sell Value |
$0 |
$0 |
$0 |
$88,083 |
| Total People Sold |
0 |
0 |
0 |
7 |
| Total Sell Transactions |
0 |
0 |
0 |
15 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Peters Richard |
President and CEO |
• • – |
2022-06-03 |
4 |
S |
$1.19 |
$12,192 |
D/D |
(10,206) |
105,502 |
|
-19% |
|
| Wyzga Michael D |
See Remarks |
• – – |
2022-06-03 |
4 |
S |
$1.19 |
$3,449 |
D/D |
(2,887) |
17,113 |
|
-19% |
|
| Peters Richard |
President and CEO |
• • – |
2022-03-28 |
4 |
AS |
$1.85 |
$19,775 |
D/D |
(10,715) |
115,708 |
|
-6% |
|
| Mohsen Paulash |
Chief Business Officer |
• – – |
2022-02-03 |
4 |
S |
$1.83 |
$3,583 |
D/D |
(1,958) |
59,135 |
|
11% |
|
| Smith Devin Whittemore |
SVP and General Counsel |
• – – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Wyzga Michael D |
See Remarks |
• – – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Epstein Marie |
Principal Accounting Officer |
• – – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,665 |
12,665 |
|
- |
|
| Verma Ajay |
EVP, Head of R&D |
• – – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Peters Richard |
President and CEO |
• • – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
126,423 |
|
- |
|
| Mohsen Paulash |
Chief Business Officer |
• – – |
2021-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
61,093 |
|
- |
|
| Peters Richard |
President and CEO |
• • – |
2021-07-06 |
4 |
D |
$10.79 |
$852 |
D/D |
(79) |
56,423 |
|
- |
|
| Peters Richard |
President and CEO |
• • – |
2021-07-02 |
4 |
D |
$11.11 |
$49,340 |
D/D |
(4,441) |
56,502 |
|
- |
|
| Verma Ajay |
EVP, Head of R&DOfficer |
• – – |
2021-04-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
200 |
|
-51% |
|
| Pickett Cecil B |
Director |
– • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,959 |
8,117 |
|
- |
|
| Peters Richard |
President & CEO |
• • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
60,943 |
60,943 |
|
- |
|
| Kelly Jeffrey W. |
Director |
– • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,959 |
13,237 |
|
- |
|
| Coles N Anthony |
Executive Chair |
• • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,118 |
691,008 |
|
- |
|
| Heyman Richard A. |
Director |
– • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,959 |
8,117 |
|
- |
|
| Mohsen Paulash |
Chief Business Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,665 |
41,093 |
|
- |
|
| Arkowitz David |
Director |
– • – |
2020-12-22 |
4 |
A |
$23.00 |
$99,981 |
D/D |
4,347 |
4,347 |
|
- |
|
| Kelly Jeffrey W. |
Director |
– • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,158 |
11,278 |
|
- |
|
| Pickett Cecil B |
Director |
– • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,158 |
6,158 |
|
- |
|
| Coles N Anthony |
Executive Chair |
• • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
I/I |
52,669 |
52,669 |
|
- |
|
| Coles N Anthony |
Executive Chair |
• • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
689,890 |
689,890 |
|
- |
|
| Heyman Richard A. |
Director |
– • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,158 |
6,158 |
|
- |
|
147 Records found
|
|
Page 3 of 6 |
|
|
